Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLD Boundless Bio	$1.12 -51.3%	$59.97	$1.00 ▼ $4.72	$25.52M	-1.23	74,845 shs	96,520 shs
OBIO Orchestra BioMed	$2.74 +1.0%	$2.88	$2.37 ▼ $7.04	$105.77M	0.62	299,538 shs	105,625 shs
ONCY Oncolytics Biotech	$1.04 -3.3%	$0.99	$0.33 ▼ $1.53	$103.87M	1.09	965,587 shs	532,505 shs
XBIT XBiotech	$3.16 -6.9%	$3.00	$2.50 ▼ $8.32	$96.20M	0.97	67,314 shs	24,390 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLD Boundless Bio	-1.31%	-2.16%	-3.00%	+2.73%	-68.52%
OBIO Orchestra BioMed	-4.58%	+8.84%	-14.24%	-4.91%	-58.18%
ONCY Oncolytics Biotech	+0.94%	+5.94%	+4.90%	+202.60%	+11.54%
XBIT XBiotech	-2.59%	+5.94%	+18.53%	+19.37%	-49.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BOLD Boundless Bio	2.0268 of 5 stars	3.1	3.0	0.0	1.7	1.3
OBIO Orchestra BioMed	3.3583 of 5 stars	3.5	5.0	3.3	2.5	0.0
ONCY Oncolytics Biotech	1.8041 of 5 stars	3.4	3.0	2.6	0.0	0.0
XBIT XBiotech	1.6327 of 5 stars	0.0	4.0	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLD Boundless Bio	2.25	Hold	$3.50	212.50% Upside
OBIO Orchestra BioMed	3.00	Buy	$14.00	411.51% Upside
ONCY Oncolytics Biotech	2.80	Moderate Buy	$5.00	383.09% Upside
XBIT XBiotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BOLD, OBIO, ONCY, and XBIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	OBIO Orchestra BioMed	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
8/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/13/2025	ONCY Oncolytics Biotech	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/11/2025	BOLD Boundless Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
8/7/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/2/2025	BOLD Boundless Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLD Boundless Bio	N/A	N/A	N/A	N/A	$5.48 per share	N/A
OBIO Orchestra BioMed	$2.94M	35.93	N/A	N/A	$0.01 per share	273.70
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.04 per share	N/A
XBIT XBiotech	$4.01M	23.99	N/A	N/A	$5.68 per share	0.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLD Boundless Bio	-$65.36M	N/A	N/A	N/A	N/A	N/A	-44.79%	-34.24%	N/A
OBIO Orchestra BioMed	-$61.02M	-$1.83	N/A	N/A	N/A	-2,367.49%	-289.42%	-110.04%	11/11/2025 (Estimated)
ONCY Oncolytics Biotech	-$23.14M	-$0.27	N/A	N/A	N/A	N/A	-438.11%	-143.90%	11/11/2025 (Estimated)
XBIT XBiotech	-$38.53M	-$0.92	N/A	∞	N/A	N/A	-15.60%	-14.64%	11/11/2025 (Estimated)

Latest BOLD, OBIO, ONCY, and XBIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	XBIT XBiotech	N/A	-$0.06	N/A	-$0.06	N/A	N/A
8/12/2025	Q2 2025	OBIO Orchestra BioMed	-$0.51	-$0.50	+$0.01	-$0.50	$0.78 million	$0.84 million
8/8/2025	Q2 2025	ONCY Oncolytics Biotech	-$0.11	-$0.05	+$0.06	-$0.05	N/A	N/A
8/5/2025	Q2 2025	BOLD Boundless Bio	-$0.75	-$0.70	+$0.05	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLD Boundless Bio	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLD Boundless Bio	0.39	14.08	14.08
OBIO Orchestra BioMed	48.76	2.10	2.09
ONCY Oncolytics Biotech	N/A	2.88	2.88
XBIT XBiotech	N/A	40.16	40.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLD Boundless Bio	N/A
OBIO Orchestra BioMed	53.20%
ONCY Oncolytics Biotech	6.82%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
BOLD Boundless Bio	21.10%
OBIO Orchestra BioMed	8.10%
ONCY Oncolytics Biotech	0.10%
XBIT XBiotech	30.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLD Boundless Bio	207	22.39 million	17.66 million	No Data
OBIO Orchestra BioMed	4	38.64 million	35.51 million	Not Optionable
ONCY Oncolytics Biotech	30	100.36 million	100.26 million	Not Optionable
XBIT XBiotech	100	30.49 million	21.10 million	Optionable

BOLD, OBIO, ONCY, and XBIT Headlines

Recent News About These Companies

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders

August 28 at 7:46 AM | finance.yahoo.com

XBiotech (NASDAQ:XBIT) Share Price Passes Above Fifty Day Moving Average - What's Next?

August 22, 2025 | marketbeat.com

XBiotech (NASDAQ:XBIT) Releases Quarterly Earnings Results

August 16, 2025 | marketbeat.com

XBiotech Inc. (NASDAQ:XBIT) Short Interest Up 452.0% in July

August 2, 2025 | marketbeat.com

XBiotech (NASDAQ:XBIT) Stock Price Passes Below Fifty Day Moving Average - Should You Sell?

August 1, 2025 | marketbeat.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 22, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 21, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 20, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 18, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 17, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 16, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 15, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 14, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD, OBIO, ONCY, and XBIT Company Descriptions

Boundless Bio NASDAQ:BOLD

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Orchestra BioMed NASDAQ:OBIO

$2.74 +0.03 (+1.00%)

Closing price 03:59 PM Eastern

Extended Trading

$2.78 +0.04 (+1.57%)

As of 04:04 PM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Oncolytics Biotech NASDAQ:ONCY

$1.03 -0.04 (-3.27%)

Closing price 03:59 PM Eastern

Extended Trading

$1.03 0.00 (0.00%)

As of 04:04 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

XBiotech NASDAQ:XBIT

$3.16 -0.24 (-6.93%)

Closing price 03:59 PM Eastern

Extended Trading

$3.16 0.00 (0.00%)

As of 04:04 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time